Your session is about to expire
← Back to Search
Anastrozole for Breast Cancer
Study Summary
This trial is testing anastrozole and letrozole to see if they can help treat stage I-III breast cancer patients and prevent cancer from recurring.
- Breast Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 79 Patients • NCT02137538Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- If necessary, you have received radiation therapy after surgery.You may need chemotherapy before or after the study.You have received treatment with a medication called an aromatase inhibitor or selective estrogen receptor modulator (SERM) in the past. However, if you stopped taking SERM (tamoxifen or raloxifene) at least 6 months ago, you may still be eligible for the study.You have a stage I-III breast cancer.You started taking bisphosphonate medication less than 4 weeks ago.You may need radiation therapy after surgery.You have ER positive disease according to ASCO/CAP guidelines as ER > 1% positive nuclear staining.You have had a previous instance of DCIS or invasive breast cancer in the opposite breast.You may need to receive chemotherapy before or after the study.You can swallow pills or tablets.
- Group 1: Treatment (anastrozole, letrozole)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are Anastrozole's common applications in medication?
"Anastrozole is often used as part of a tamoxifen treatment plan that lasts two to three years. Additionally, it can be given to postmenopausal women and those with early-stage breast cancer that has spread beyond the milk ducts."
Are there any dangers associated with Anastrozole?
"Since Anastrozole is in Phase 2 clinical trials, there is not yet data supporting its efficacy. However, it has been deemed safe enough to progress to this stage of testing, so our team gives it a score of 2."
Are there other examples in which Anastrozole has been used in research?
"As of now,185 active clinical studies are investigating Anastrozole with 49 of them being in Phase 3. Although a concentration of these trials for Anastrozole is based in San Francisco, CA, there are 13,838 total locations running trials for this medication."
Are we still enrolling people in this experiment?
"This study, which is currently recruiting participants, was originally posted on April 28th 2020. The last edit to the posting was made on May 31st 2022."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Mayo Clinic in Arizona: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger